Abstracts Archive - Page 1808 of 2607 - ACR Meeting Abstracts

Abstract Number: 3139 • 2016 ACR/ARHP Annual Meeting
Breaking the Cycle: Analyzing Preventable Hospital Admissions Due to Gout
Pieusha Malhotra¹, Nikky Keer² and Robert Yood³, ¹Internal Medicine, Department of Medicine, Division of Rheumatic Diseases and Musculoskeletal Medicine, Saint Vincent Hospital, Worcester, MA, ²Internal medicine, Department of Medicine, Division of Rheumatic Diseases and Musculoskeletal Medicine, Saint Vincent Hospital, Worcester, MA, ³Department of rheumatology and musculoskeletal medicine, Department of Medicine, Division of Rheumatic Diseases and Musculoskeletal Medicine, Saint Vincent Hospital, Worcester, MA
Background/Purpose: Despite available effective treatment options and published guidelines for gout management, many patients suffer from recurrent gout attacks. Increases in gout prevalence and continued…
Abstract Number: 3140 • 2016 ACR/ARHP Annual Meeting
Assessment of American College of Rheumatology Gout Quality Measures at a University Practice Plan
Soo Choi¹, John FitzGerald¹, Robin Clarke² and Andrew Hackbarth³, ¹Rheumatology, UCLA, Los Angeles, CA, ²Faculty Practice Group, UCLA, Los Angeles, CA, ³UCLA, Los Angeles, CA
Background/Purpose: Gout is the most common chronic inflammatory arthritis. Gout prevalence has been rising over the past several decades, and gout is associated with significant…
Abstract Number: 3141 • 2016 ACR/ARHP Annual Meeting
Development of a Glucocorticoid Toxicity Index Using Multi-Criteria Decision Analysis
Eli Miloslavsky¹, Raymond P. Naden², Johannes WJ Bijlsma³, Paul Brogan⁴, Sherwood Brown⁵, Paul Brunetta⁶, Frank Buttgereit⁷, Hyon K. Choi⁸, Jean-Francois Dicaire⁹, Jeffrey Gelfand¹⁰, Liam Heaney¹¹, Liz Lightstone¹², Leo Lu¹³, Dedee Murrell¹⁴, Michelle Petri¹⁵, James T. Rosenbaum¹⁶, Kenneth Saag¹⁷, Murray Urowitz¹⁸, Kevin L Winthrop¹⁹ and John H. Stone²⁰, ¹Division of Rheumatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²New Zealand Ministry of Health, New Zealand Ministry of Health, Auckland, New Zealand, ³ARC, Amsterdam, Netherlands, ⁴Department of Paediatric Rheumatology, UCL Institute of Child Health and Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom, ⁵Psychiatry, UT Southwestern Medical Center, Dallas, TX, ⁶Genentech, Inc., South San Francisco, CA, ⁷Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, Berlin, Germany, ⁸Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁹Pinnacle Inc., Quebec, QC, Canada, ¹⁰Neurology, University of California San Francisco, San Francisco, CA, ¹¹Department of Respiratory Medicine, Queen's University Belfast, Belfast, Ireland, ¹²Department of Medicine, Imperial College London, London, England, ¹³Allergy, Immunology, and Rheumatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ¹⁴Department of Dermatology, University of New South Wales, Sydney, Australia, ¹⁵Rheumatology Division, Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁶Oregon Health & Science University, Portland, OR, ¹⁷Division of Clinical Immunology and Rheumatology, University of Alabama Birmingham School of Medicine, Birmingham, AL, ¹⁸Medicine, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ¹⁹Oregon Health and Sciences University, Portland, OR, ²⁰Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA
Background/Purpose: Glucocorticoids (GC) are associated with substantial treatment morbidity. New immunomodulatory agents offer the possibility of limiting GC exposure. To assess the comparative benefits of…
Abstract Number: 3142 • 2016 ACR/ARHP Annual Meeting
Improving Counseling, Documentation and Adherence to Highly Effective Birth Control in Women on Teratogenic Medications at a Rural Medical Center: A Quality Improvement Initiative
Sonal Bhalla^1,2,3, John Mecchella^1,4 and Alicia Zbehlik^1,4,5, ¹Rheumatology, Dartmouth-Hitchcock Medical Center, Lebanon, NH, ²Rheumatology/ Leardership Peventive Medicine Residency, Dartmouth-Hitchcock Medical Center, Lebanon, NH, ³Instructor in Medicine, Geisel School of Medicine at Dartmouth, Hanover, NH, ⁴Geisel School of Medicine at Dartmouth, Hanover, NH, ⁵Leadership Preventive Medicine/Rheumatology, Dartmouth-Hitchcock Medical Center, Lebanon, NH
Background/Purpose: Autoimmune and inflammatory diseases occur more often in women than in men, and often these women are of childbearing age. Many of the medications…
Abstract Number: 3143 • 2016 ACR/ARHP Annual Meeting
The Caspase 8/RIPK3 Signaling Axis in Dendritic Cells Controls Joint Homeostasis Under Steady-State and Arthritic Conditions
Salina Dominguez¹, Harris R. Perlman² and Carla Cuda¹, ¹Northwestern University, Chicago, IL, ²Department of Medicine, Division of Rheumatology, Northwestern University Feinberg School of Medicine, Northwestern University, Chicago, IL
Background/Purpose: Rheumatoid arthritis (RA) manifests in persistent synovial inflammation, cellular infiltration and pro-inflammatory cytokine production, and results in progressive joint destruction. Dendritic cells (DCs) have…
Abstract Number: 3144 • 2016 ACR/ARHP Annual Meeting
Role of the Gut Microbiome in Modulating Arthritis Progression in Mice
Xiao fei Liu¹, Qing hua Zou¹, Bing Zhong¹ and Yong fei Fang², ¹Southwest Hospital, Third Military Medical University, chongqing, China, ²Department of Rheumatology, Southwest Hospital, Third Military Medical University, chongqing, China
Abstract Background/Purpose: Genetics alone cannot explain most cases of rheumatoid arthritis (RA). Thus, investigating environmental factors such as the gut microbiota may provide new insights…
Abstract Number: 3146 • 2016 ACR/ARHP Annual Meeting
Selective Deletion of a Pathogenic Subset Synovial Fibroblasts Attenuates Synovial Inflammation
Adam Paul Croft, Joana Campos, Andrew Filer, Francesca Barone and Chris Buckley, Institute of Inflammation and Ageing (IIA), University of Birmingham, Birmingham, United Kingdom
Background/Purpose: Despite their role as key effector cells driving synovial inflammation and joint damage, fibroblast like synoviocytes (FLS) have yet to be targeted therapeutically. Fibroblast…
Abstract Number: 3147 • 2016 ACR/ARHP Annual Meeting
Remote Inflammation Triggers Autoimmune Arthritis through Th17 Distribution
Nina Chevalier¹, Jian Tan², Linda Mason², Remy Robert², Craig McKenzie², Seth Masters³ and Charles Mackay², ¹University Freiburg Medical Center, Freiburg, Germany, ²Monash University, Melbourne, Australia, ³WEHI, Melbourne, Australia
Background/Purpose: Autoimmune diseases, such as autoimmune inflammatory arthritis, result through breakdown of immune tolerance and development of self-reactive T cells, or autoantibody-producing B cells. Tolerance…
Abstract Number: 3148 • 2016 ACR/ARHP Annual Meeting
Peptidylarginine Deiminase 2 Is Required for Tumor Necrosis Factor Alpha Induced Citrullination and Arthritis, but Not Neutrophil Extracellular Trap Formation
Mandar Bawadekar¹, Daeun Shim¹, Ryan Rebernick¹, Chloe Peyton¹, Chad J. Johnson², Thomas F. Warner³, Dres Damgaard⁴, Claus Henrik Nielsen⁵, Anthony P. Nicholas⁶, Ger JM Pruijn⁷, Jeniel E. Nett⁸ and Miriam A. Shelef^1,9, ¹Department of Medicine, Division of Rheumatology, University of Wisconsin-Madison, Madison, WI, ²Department of Medicine, University of Wisconsin-Madison, Madison, WI, ³Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, WI, ⁴Institute for Inflammation Research, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark, ⁵Danish Rheumatologic Biobank and DANBIO registry, Rigshospitalet, Glostrup, Gentofte and Herlev University Hospital, Copenhagen, Denmark, ⁶Neurology, University of Alabama at Birmingham and Birmingham VA Medical Center, Birmingham, AL, ⁷Biomolecular Chemistry, Institute for Molecules and Materials and Radboud Institute for Molecular Life Sciences, Radboud University, Nijmegen, Netherlands, ⁸Medicine and Medical Microbiology and Immunology, University of Wisconsin-Madison, Madison, WI, ⁹William S. Middleton Memorial Veterans Hospital, Madison, WI
Background/Purpose: The presence of anti-citrullinated protein antibodies in rheumatoid arthritis points to a potential role for citrullination in disease pathogenesis. Peptidylarginine deiminases (PADs) catalyze the…
Abstract Number: 3149 • 2016 ACR/ARHP Annual Meeting
“Early Use of Subcutaneous MTX Monotherapy Vs. MTX Oral or Combination Therapy Significantly Delays Time to Initiating Biologics in Early RA
Stephanie Gottheil¹, J Carter Thorne², Orit Schieir³, Gilles Boire⁴, Boulos Haraoui⁵, Carol Hitchon⁶, Diane Tin⁷, Cheryl Barnabe⁸, Glen Hazlewood⁸, Edward Keystone⁹, Vivian P. Bykerk¹⁰, Janet E. Pope¹¹, Susan J. Bartlett¹² and Canadian Early Arthritis Cohort, ¹University of Western Ontario, LONDON, ON, Canada, ²Southlake Regional Health Centre, Newmarket, ON, Canada, ³McGill University, Montreal, ON, Canada, ⁴Rheumatology Division, CHUS - Sherbrooke University, Sherbrooke, QC, Canada, ⁵Institute de Rheumatologie, Montreal, QC, Canada, ⁶University of Manitoba, Winnipeg, MB, Canada, ⁷The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ⁸Division of Rheumatology, University of Calgary, Calgary, AB, Canada, ⁹Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada, ¹⁰Divison of Rheumatology, Hospital for Special Surgery, New York, NY, ¹¹University of Western Ontario, St Joseph's Health Care, London, ON, Canada, ¹²Department of Medicine, Division of ClinEpi, Rheumatology, Respirology, McGill University, Montreal, QC, Canada
Background/Purpose: Optimal treatment for moderate-severe early rheumatoid arthritis involves using a methotrexate-based, treat-to-target strategy aiming for remission. Achieving remission without using biologics may be preferable…
Abstract Number: 3150 • 2016 ACR/ARHP Annual Meeting
The Initial Dose of Methotrexate per Weight Is Determinant of Disease Activity and Early DAS28 Remission in DMARD-Naive Early Rheumatoid Arthritis Patients Receiving Usual Care
Tuomas Rannio¹, Juha Asikainen², Pekka Hannonen², Timo Yli-Kerttula³, Päivi Ekman⁴, Laura Kuusalo⁵, Laura Pirilä⁶, Markku Mali⁷, Marja Puurtinen-Vilkki⁷, Satu Kortelainen⁷, Johanna Paltta⁶, Kirsi Taimen⁷, Markku J. Kauppi⁸, Kari Laiho⁹, Satu Nyrhinen⁹, Heidi Mäkinen¹⁰, Pia Isomäki¹⁰, Terhi Uotila¹⁰, Kalle Aaltonen¹¹, Hannu Kautiainen¹² and Tuulikki Sokka-Isler¹, ¹Rheumatology, Jyvaskyla Central Hospital, Jyvaskyla, Finland, ²Jyvaskyla Central Hospital, Jyväskylä, Finland, ³Sairaalantie 3, Satakunta Central Hospital, Rauma, Finland, ⁴Satakunta Central Hospital, Rauma, Finland, ⁵Rheumatology, Turku University Central Hospital, Turku, Finland, ⁶Turku University Hospital, Turku, Finland, ⁷Turku University Central Hospital, Turku, Finland, ⁸Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland, ⁹Päijät-Häme Central Hospital, Lahti, Finland, ¹⁰Tampere University Hospital, Tampere, Finland, ¹¹Helsinki University, Helsinki, Finland, ¹²Unit of Primary Health Care, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
Background/Purpose: Methotrexate (MTX) is considered as the anchor disease modifying antirheumatic drug (DMARD) in treatment of rheumatoid arthritis (RA). However, there is no advice…
Abstract Number: 3151 • 2016 ACR/ARHP Annual Meeting
The Diagnostic and Predictive Value of Anti-Acetylated Peptide Antibodies in RA Patients Starting Methotrexate Treatment
Paul Studenic¹, Stephan Blüml², Holger Bang³, Manuel Unger⁴, Karim Raza⁵, Daniel Aletaha⁶, Josef S. Smolen^7,8 and Günter Steiner⁹, ¹Department of Internal Medicine 3, Division of Rheumatology and Geriatric Medicine, Medical University Vienna, Vienna, Austria, ²Internal Medicine 3; Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ³Rsearch & Development, Orgentec Diagnostika GmbH, Mainz, Germany, ⁴Department of Internal Medicine 3, Division of Rheumatology, Medical University Vienna, Vienna, Austria, ⁵University of Birmingham, Rheumatology Research Group, Institute of Inflammation and Ageing, United Kingdom, Birmingham, United Kingdom, ⁶Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ⁷2nd Department of Medicine, Hietzing Hospital, Vienna, Austria, ⁸Department of Medicine 3, Division of Rheumatology, Medical University Vienna, Vienna, Austria, ⁹Internal Medicine 3, Division of Rheumatology, Medical University Vienna, Vienna, Austria
Background/Purpose: Anti-acetylated-peptide antibodies (AAPA) have recently been described in rheumatoid arthritis (RA) patients and may be used as a further diagnostic marker in patients with…
Abstract Number: 3152 • 2016 ACR/ARHP Annual Meeting
Rheumatoid Arthritis (RA): Premature Use of Biologics Accelerating in United States (US)
James R. O'Dell¹, Stanley B. Cohen², J Carter Thorne³ and Ted R Mikuls⁴, ¹Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ²Metroplex Clinical Research Center, Dallas, TX, ³Southlake Regional Health Centre, Newmarket, ON, Canada, ⁴Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: The treatment of RA has changed dramatically in the past several decades with the advent of a large number of new biologic agents as…
Abstract Number: 3153 • 2016 ACR/ARHP Annual Meeting
Automated Cell Phone Monitoring of Disease Activity and Medication Adherence in Early Rheumatoid Arthritis
Laura Kuusalo^1,2, Hannu Kautiainen³, Tuulikki Sokka-Isler⁴, Toini Uutela⁵, Laura Pirilä², Timo Yli-Kerttula⁶, Markku J Kauppi^7,8, Tuomas Rannio⁹, Kirsi Paalanen¹⁰, Arto Kokko⁹, Juha Asikainen⁹, Jelena Borodina¹⁰, Johanna Paltta², Kari Laiho¹¹, Andrus Mullanmaa¹², Kari Puolakka¹² and SandRA Study Group, ¹University of Turku, Turku, Finland, ²Turku University Hospital, Turku, Finland, ³Unit of Primary Health Care, University of Helsinki and Helsinki University Hospital, Helsinki, Finland, ⁴Rheumatology, Jyvaskyla Central Hospital, Jyvaskyla, Finland, ⁵Lapland Central Hospital, Rovaniemi, Finland, ⁶Sairaalantie 3, Satakunta Central Hospital, Rauma, Finland, ⁷School of Medicine, University of Tampere, Tampere, Finland, ⁸Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland, ⁹Jyvaskyla Central Hospital, Jyväskylä, Finland, ¹⁰Jyvaskyla Central Hospital, Jyvaskyla, Finland, ¹¹Päijät-Häme Central Hospital, Lahti, Finland, ¹²South Karelia Central Hospital, Lappeenranta, Finland
Background/Purpose: Remission targeted treatment of early RA requires frequent monitoring. However, in clinical practice monitoring frequency is not always optimal due to factors like limited…
Abstract Number: 3154 • 2016 ACR/ARHP Annual Meeting
Assessing Bone Erosions in the Metatarsophalangeal Joints of Patients with Early Rheumatoid Arthritis: a Comparison Between MRI and Ultrasound
Karen A. Beattie¹, Sydney Scheffler², George Ioannidis³, Edward Schreyer⁴, Saara Totterman⁵ and Maggie Larche¹, ¹Medicine, McMaster University, Hamilton, ON, Canada, ²McMaster University, Hamilton, ON, Canada, ³St Joseph's Healthcare Hamilton, Hamilton, ON, Canada, ⁴QMetrics Technologies, Rochester, NY, ⁵Radiology, VirtualScopics Inc., Rochester, NY
Background/Purpose: This cross-sectional study aimed to assess the agreement between Magnetic Resonance Imaging (MRI) and ultrasound (US) findings of bone erosions in the metatarsalphalangeal (MTP)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].